Product
AMP945
Aliases
AMP945 ascending doses, AMP945 RP2D
1 clinical trial
3 indications
Indication
Pancreatic CancerIndication
PDACIndication
Pancreatic Ductal AdenocarcinomaClinical trial
A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination With Nab-paclitaxel and Gemcitabine in Pancreatic Cancer PatientsStatus: Recruiting, Estimated PCD: 2025-05-01